Sentinel lymph node B cells can predict disease-free survival in breast cancer patients.

NPJ Breast Cancer
Kim R M BlenmanPeter P Lee

Abstract

Tumor invasion into draining lymph nodes, especially sentinel lymph nodes (SLNs), is a key determinant of prognosis and treatment in breast cancer as part of the TNM staging system. Using multicolor histology and quantitative image analysis, we quantified immune cells within SLNs from a discovery cohort of 76 breast cancer patients. We found statistically more in situ CD3+ T cells in tumor negative vs. tumor positive nodes (mean of 8878 vs. 6704, respectively, p = 0.006), but no statistical difference in CD20+ B cells or CD1a+ dendritic cells. In univariate analysis, a reduced hazard was seen with a unit increase in log CD3 with HR 0.49 (95% CI 0.30-0.80) and log CD20 with HR 0.37 (95% CI 0.22-0.62). In multivariate analysis, log CD20 remained significant with HR 0.42 (95% CI 0.25-0.69). When restricted to SLN tumor negative patients, increased log CD20 was still associated with improved DFS (HR = 0.26, 95% CI 0.08-0.90). The CD20 results were validated in a separate cohort of 21 patients (n = 11 good outcome, n = 10 poor outcome) with SLN negative triple-negative breast cancer (TNBC) ("good" mean of 7011 vs. "poor" mean of 4656, p = 0.002). Our study demonstrates that analysis of immune cells within SLNs, regardless of tumor i...Continue Reading

References

Aug 9, 2003·The New England Journal of Medicine·Umberto VeronesiRoberto Gennari
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Sep 2, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giampaolo BianchiniLajos Pusztai
Feb 10, 2011·JAMA : the Journal of the American Medical Association·Armando E GiulianoMonica Morrow
Jun 15, 2011·Breast Cancer Research and Treatment·S M A MahmoudA R Green
Mar 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanUNKNOWN American Society of Clinical Oncology Clinical Practice
May 27, 2014·Frontiers in Immunology·Alexandre Corthay
Sep 16, 2015·Annals of Surgical Oncology·Siem A DingemansAnne E M van der Pool
Feb 1, 2018·Journal of Immunological Methods·Girja S ShuklaDavid N Krag
Feb 3, 2018·Cancer Management and Research·Claudia OmariniFederico Piacentini
Feb 11, 2018·Cancer Immunology, Immunotherapy : CII·Jonathan R McDanielDavid N Krag

❮ Previous
Next ❯

Citations

Nov 24, 2018·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Kim R M Blenman, Marcus W Bosenberg
Feb 1, 2019·Pigment Cell & Melanoma Research·Kim R M BlenmanMarcus Bosenberg
Oct 16, 2018·Frontiers in Immunology·Antigoni PoultsidiConstantinos Petrovas
Nov 18, 2020·Journal for Immunotherapy of Cancer·Chiara MassaBarbara Seliger
May 28, 2021·The American Journal of Pathology·Samir JanaDennis Jones

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection
biopsies

Software Mentioned

SAS
CRI
R

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.